Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation
Huang D, Guan Q, Qin J, Shan R, Wu J, Zhang C (2022) · Perfusion · n=1232
Study Profile
- Design
- systematic review and meta-analysis of 12 retrospective cohort studies through April 2022 (PubMed, Embase, Cochrane Library)
- Pooled sample (n; included studies may overlap)
- 1232
- Scope
- Bivalirudin anticoagulation for ECMO (n=497 across pooled cohorts)
- Main result
- No significant difference in mortality (RR 0.95, 95% CI 0.79-1.13, p=0.546) or thrombotic events (RR 0.78, 95% CI 0.45-1.35); bivalirudin significantly reduced bleeding events (RR 0.48, 95% CI 0.25-0.95, p=0.035)
- PMID
- 35616224
Key Findings
- Largest contemporary pooled dataset (n=1,232) on ECMO anticoagulation choice
- Equivalent mortality between bivalirudin and heparin
- Equivalent thrombotic event rates
- Bivalirudin associated with reduced bleeding complications (52% relative reduction)
- Highlights need for prospective RCTs
Limitations
- All included studies were retrospective observational
- Significant clinical heterogeneity across centers
- Publication bias likely
- Patient selection bias - sicker patients more likely to receive bivalirudin
- Not applicable to whole-leech hirudotherapy
Clinical Implications
Huang 2022 is a foundational evidence synthesis for ECMO anticoagulation choice. For ASH, the meta-analysis demonstrates how the synthetic hirudin-derivative pathway operates under retrospective observational evidence with bleeding-reduction signal but no mortality benefit. This evidence base is structurally distinct from the device-leech K040187 US practice and serves as a reference for the broader hirudin-derived anticoagulant landscape.
Related studies
Comparison of Bivalirudin Versus Heparin for Anticoagulation During Extracorporeal Membrane Oxygenation
Hasegawa D, Sato R, Prasitlumkum N, Nishida K, Keaton B, Acquah SO, Im Lee Y (2022)
Heparin Versus Bivalirudin for Anticoagulation in Adult Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis
Wieruszewski PM, Macielak SA, Nei SD, Moman RN, Seelhammer TG, Nabzdyk CGS, Gerberi DJ, Mara KC, Hooten WM, Wittwer ED (2022)
Is bivalirudin an alternative anticoagulant for extracorporeal membrane oxygenation (ECMO) patients? A systematic review and meta-analysis
Li DH, Sun MW, Zhang JC, Zhang C, Deng L, Jiang H (2021)
Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation
McMichael A, Weller J, Li X, Hatton L, Zia A, Raman L (2024)